Cite
HARVARD Citation
Akkus, M. et al. (2021). Alectinib continuation during COVID 19 'antiviral' treatment: Risk or benefit?. Journal of oncology pharmacy practice. pp. 1251-1254. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Akkus, M. et al. (2021). Alectinib continuation during COVID 19 'antiviral' treatment: Risk or benefit?. Journal of oncology pharmacy practice. pp. 1251-1254. [Online].